Embecta delivers treatment to diabetes patients and is a spin-off from Beckton, Dickinson, and Co. Embecta listed on the Nasdaq under the ticker symbol EMBC. The company is a leading producer of diabetes injection devices, manufacturing approximately 8 billion injection devices annually for about 30 million patients across more than 100 countries. CEO Dev Kurdikar discusses Embecta as a product innovator, industry leader with a global and serviceable need.
The Watch List
01 Apr 2022
SHARE
Market On Close
22 Feb 2023
Morning Trade Live
14 Feb 2023
Morning Trade Live
05 Jan 2023
Trading 360
06 Jan 2023
The Watch List
20 Jan 2023
Trading 360
16 Mar 2023